| Name | Title | Contact Details |
|---|---|---|
Donald Healey |
Chief Technology Officer | Profile |
Elizabeth Read |
Chief Technology Officer | Profile |
Elizabeth Read |
Chief Technology Officer | Profile |
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.
Suncoast Perfusion Services is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A New Dawn for Central Nervous System Treatments GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drugs dual mechanism of action may also benefit ...